EKSO Stock Overview
Designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Ekso Bionics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.54 |
| 52 Week High | US$2.32 |
| 52 Week Low | US$0.47 |
| Beta | 1.46 |
| 1 Month Change | -34.88% |
| 3 Month Change | -37.15% |
| 1 Year Change | -73.24% |
| 3 Year Change | -79.21% |
| 5 Year Change | -90.15% |
| Change since IPO | -99.78% |
Recent News & Updates
Even With A 39% Surge, Cautious Investors Are Not Rewarding Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Performance Completely
Jan 12
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper
Nov 12Recent updates
Even With A 39% Surge, Cautious Investors Are Not Rewarding Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Performance Completely
Jan 12Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper
Nov 12Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding
Aug 29Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Jul 13Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00
May 02Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Dec 20Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Jun 19Ekso Bionics: Fragile Opportunity
Aug 24Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?
Jun 14Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?
Feb 05Shareholder Returns
| EKSO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.6% | 1.6% | 0.6% |
| 1Y | -73.2% | 14.0% | 22.4% |
Return vs Industry: EKSO underperformed the US Medical Equipment industry which returned 14% over the past year.
Return vs Market: EKSO underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| EKSO volatility | |
|---|---|
| EKSO Average Weekly Movement | 13.4% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: EKSO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EKSO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 71 | Scott Davis | www.eksobionics.com |
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Ekso Bionics Holdings, Inc. Fundamentals Summary
| EKSO fundamental statistics | |
|---|---|
| Market cap | US$12.09m |
| Earnings (TTM) | -US$11.13m |
| Revenue (TTM) | US$17.68m |
0.7x
P/S Ratio-1.1x
P/E RatioIs EKSO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKSO income statement (TTM) | |
|---|---|
| Revenue | US$17.68m |
| Cost of Revenue | US$8.52m |
| Gross Profit | US$9.17m |
| Other Expenses | US$20.30m |
| Earnings | -US$11.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 51.84% |
| Net Profit Margin | -62.95% |
| Debt/Equity Ratio | 36.0% |
How did EKSO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 01:04 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ekso Bionics Holdings, Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Craig Bijou | Cantor Fitzgerald & Co. |
| Gregory Chodaczek | CRT Capital Group |